Effectiveness And Impact Of Nirsevimab In Chile (NIRSE-CL)

Launched by INSTITUTO SISTEMAS COMPLEJOS DE INGENIERÍA · Jul 15, 2024

Keywords

ClinConnect Summary

The Nirse-CL study is investigating how well a medication called nirsevimab can help prevent respiratory syncytial virus (RSV) infections in infants in Chile. RSV is a common virus that can cause serious respiratory issues in young children. This study will look at data from various health sources before, during, and after a new immunization program to see how effective nirsevimab is in keeping babies healthy and reducing RSV-related health problems.

To be part of the study, infants must be born between October 1, 2023, and September 30, 2024, or be preterm babies born at 29 weeks or less during specific dates. Those with certain lung conditions or low birth weight may also qualify. Participants will be monitored to see how well the medication works in preventing RSV. This study is important because it aims to improve the health outcomes of infants at risk for RSV, and the findings could help shape future immunization programs.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects born between October 1st, 2023, to September 31st, 2024.
• • Subjects born with 29 weeks of gestational age (wga) or less who were born between July 1st, 2023 and October 1st, 2023
• • Subjects born with Bronchopulmonary Dysplasia (BPD), 32 or less wga and/or a birth weight less than 1·5 kgs born between April 1st, 2023 and October 1st, 2023.
• Exclusion Criteria:
• • No specific criteria has been reported